UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

———————

FORM 10-Q

———————

(Mark one)

þ  Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934

(Mark one)
þQuarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended July 31, 2009

April 30, 2010

Or

¨  Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934

oTransition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number:  333-23460

———————

MERA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

———————


(Exact name of Registrant as specified in its charter)

Delaware

04-3683628

(State or other jurisdiction of
incorporation or organization)

(IRS Employer
Identification Number)


73-4460 Queen Ka'ahumanu Highway, Suite 110

Kailua-Kona, Hawaii  96740

(808) 326-9301

(Address

 (Address and telephone number of principal executive offices)


Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES þ   NO ¨

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.  YES þ   NO ¨

547,769,915 shares of $0.0001 par value common stock outstanding as of July 31, 2009

80 shares of $0.0001 par value Series A preferred stock outstanding as of July 31, 2009

974 shares of $0.0001 par value Series B preferred stock outstanding as of July 31, 2009





MERA PHARMACEUTICALS, INC.

FORM 10-Q
FOR THE QUARTER ENDED JULY 31, 2009

CONTENTS

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  þ       NOo

Page

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.    YES  þ      NO  o

PART

547,769,915 shares of $0.0001 par value common stock outstanding as of April 30, 2010
80 shares of $0.0001 par value Series A preferred stock outstanding as of April 30, 2010
974 shares of $0.0001 par value Series B preferred stock outstanding as of April 30, 2010




Mera Pharmaceuticals, Inc.
Form 10-Q
For the Quarter Ended April 30, 2010
Contents

Page
Part I - FINANCIAL INFORMATION

Financial Information

Item 1:  Financial Statements

3

Condensed Balance Sheet

3

1
Condensed StatementStatements of Operations

4

2
Condensed Statements of Cash Flows

5

3
Notes to Condensed Financial Statements

6

4
Item 2:  Management's Plan of Operation8
Management's Discussion and Analysis of Financial Condition and Results of Operations

9

8
Item 3:3.  Controls and Procedures

10


PART

Part II - OTHER INFORMATION


Other Information

Item 1:  Legal Proceedings

11

Item 2:  Changes In Securities

11

Item 3:3.  Defaults Upon Senior Securities

11

Item 4:  Submission of Matters to a Vote of Security Holders

(Removed and Reserved)

11

Item 5:  Other Information

11

Item 6:  Exhibits and Reports on Form 8-K

11

Signatures

12

Signature13
Certifications






PART

i

Part I - FINANCIAL INFORMATION

Financial Information

ITEM

Item 1:

FINANCIAL STATEMENTS

MERA PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEET

(UNAUDITED)

 

 

July 31,
2009

 

October 31,
2008

 

 

 

(Unaudited)

 

(Audited)

 

 

     

 

                    

     

 

                    

 

ASSETS

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

11,908

 

$

19,288

 

Marketable equitable securities

 

 

 

 

34,400

 

Accounts receivable

 

 

7,641

 

 

11,007

 

Tax credit receivable

 

 

53,591

 

 

 

Prepaid expenses and other current assets

 

 

3,809

 

 

48,580

 

 

 

 

 

 

 

 

 

Total current assets

 

 

76,949

 

 

113,275

 

 

 

 

 

 

 

 

 

Plant and equipment, net

 

 

246,824

 

 

281,439

 

 

 

 

 

 

 

 

 

Total Assets

 

$

323,773

 

$

394,714

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

310,529

 

$

283,590

 

Notes payable - related parties

 

 

51,936

 

 

51,936

 

Other current liabilities

 

 

 

 

5,412

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

362,465

 

 

340,938

 

 

 

 

 

 

 

 

 

Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

Convertible preferred stock, $.0001 par value, 10,000
shares authorized, 80 Series A shares issued and
outstanding and 974 Series B shares issued and outstanding

 

 

2

 

 

2

 

Common stock, $.0001 par value: 750,000,000
shares authorized, 547,769,915 shares issued
and outstanding

 

 

54,777

 

 

54,777

 

Additional paid-in capital

 

 

7,920,003

 

 

7,920,003

 

Treasury stock at cost

 

 

(2,025

)

 

(2,025

)

Accumulated deficit

 

 

(8,011,449

)

 

(7,918,981

)

Total stockholders' equity (deficit)

 

 

(38,692

)

 

53,776

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Equity

 

$

323,773

 

$

394,714

 

  Financial Statements

Mera Pharmaceuticals, Inc.
Condensed Balance Sheet



The

       
  
April 30,
2010
  
October 31,
2009
 
  (Unaudited)  (Audited) 
ASSETS      
Current assets:      
     Cash and cash equivalents
 $3,200  $3,135 
     Accounts receivable
  13,615   6,656 
     Tax credit receivable
  41,790   31,229 
     Prepaid expenses and other current assets
  7,983   15,994 
     Total current assets  66,588   57,014 
         
Plant and equipment, net  339,334   200,482 
         
Total Assets $405,922  $257,496 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
     Accounts payable
 $302,847  $181,040 
     Accrued expenses
  161,458   133,172 
     Notes payable - related parties
  51,936   51,936 
     Deferred revenue
  123,950   30,450 
Total Current Liabilities  640,191   396,598 
         
Contingencies        
         
Stockholders' equity:        
     Convertible preferred stock, $.0001 par value, 10,000
        
        shares authorized, 80 Series A shares issued and
        
        outstanding and 974 Series B shares issued and
        
        outstanding  2   2 
     Common stock, $.0001 par value: 750,000,000
        
        shares authorized, 547,769,915 shares issued
        
        and outstanding
  54,777   54,777 
     Additional paid-in capital
  7,920,003   7,920,003 
     Treasury stock at cost
  (2,025)  (2,025)
     Accumulated deficit
  (8,207,026)  (8,111,859)
Total stockholders' deficit  (234,269)  (139,102)
         
Total Liabilities and Stockholders' Equity $405,922  $257,496 
See the accompanying notes are an integral partto the financial statements
1


Mera Pharmaceuticals, Inc.
Condensed Statements of these financial statements


Operations

(Unaudited)


MERA PHARMACEUTICALS, INC.

CONDENSED STATEMENT OF OPERATIONS

 

 

Three Months
Ended
July 31,
2009

 

Three Months
Ended
July 31,
2008

 

Nine Months
Ended

July 31,
2009

 

Nine Months
Ended
July 31,
2008

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

     

 

                    

     

 

                    

     

 

                    

     

 

                    

 

NET SALES

 

$

106,213

 

$

173,098

 

$

500,912

 

$

455,327

 

Cost of goods sold

 

 

12,851

 

 

3,489

 

 

15,240

 

 

16,285

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

93,362

 

 

169,609

 

 

485,672

 

 

439,042

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling and administrative expenses

 

 

88,073

 

 

38,970

 

 

282,489

 

 

246,015

 

Research and development costs

 

 

82,658

 

 

64,714

 

 

252,117

 

 

184,029

 

Depreciation and amortization

 

 

21,607

 

 

69,037

 

 

64,822

 

 

213,351

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

192,338

 

 

172,721

 

 

599,428

 

 

643,395

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(98,976

)

 

(3,112

)

 

(113,756

)

 

(204,353

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

816

 

 

48

 

 

2,445

 

 

201

 

Other income

 

 

 

 

 

 

746

 

 

8,783

 

Interest expense

 

 

(1,248

)

 

(3,310

)

 

(3,781

)

 

(8,193

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total other income (expense)

 

 

(432

)

 

(3,262

)

 

(590

)

 

791

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before tax provision

 

 

(99,408

)

 

(6,374

)

 

(114,346

)

 

(203,562

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

 

 

 

 

 

 

 

Refundable tax credit

 

 

8,164

 

 

13,895

 

 

21,878

 

 

23,038

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET INCOME (LOSS)

 

$

(91,244

)

$

7,521

 

$

(92,468

)

$

(180,524

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per common share

 

$

(0.0002

)

$

0.0000

 

$

(0.0002

)

$

(0.0004

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding

 

 

547,769,915

 

 

510,369,915

 

 

547,769,915

 

 

510,369,915

 




The

  Three Months  Three Months  Six Months  Six Months 
  Ended  Ended  Ended  Ended 
  April 30, 2010  April 30, 2009  April 30, 2010  April 30, 2009 
             
             
NET SALES $61,413  $206,762  $157,628  $394,699 
Cost of Goods Sold  9,095   1,937   10,401   2,389 
                 
GROSS PROFIT  52,318   204,825   147,227   392,310 
                 
Costs and Expenses                
Research and development costs  70,474   72,788   133,406   169,459 
Selling, general and administrative  56,491   93,394   107,238   194,417 
Depreciation and Amortization  6,824   21,607   11,149   43,215 
                 
Total costs and expenses  133,789   187,789   251,793   407,091 
                 
Operating profit (loss)  (81,471)  17,036   (104,566)  (14,781)
                 
Other income (expense):                
Interest income  -   258   -   1,629 
Other income  -   -   1,333   - 
Gains on sale of marketable equitable securities  -   746   -   746 
Interest expense  (1,248)  (1,252)  (2,496)  (2,533)
                 
Total other income (expense)  (1,248)  (248)  (1,163)  (158)
                 
Net income (loss) before income tax provision  (82,719)  16,788   (105,729)  (14,939)
                 
Tax expense  -   -   -   - 
Refundable tax credit  4,941   6,133   10,561   13,714 
                 
Net income (loss) $(77,778) $22,921  $(95,168) $(1,225)
                 
Income (loss) per share - basic and diluted  (0.0001)  0.0000   (0.0002)  (0.0000)
Weighted average shares outstanding - basic and diluted
  547,769,915   547,769,915   547,769,915   547,769,915 
                 
See the accompanying notes are an integral partto the financial statements
2

Mera Pharmaceuticals, Inc.
 Condensed Statements of these financial statements


Cash Flows

(Unaudited)


MERA PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

Nine Months
Ended

July 31,
2009

 

Nine Months
Ended
July 31,
2008

 

 

 

(Unaudited)

 

(Unaudited)

 

Cash Flows from Operating Activities:

     

 

                    

     

 

                    

 

Net loss

 

$

(92,468

)

$

(180,524

)

Adjustments to reconcile net loss to net cash
used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

 

64,822

 

 

213,351

 

Changes in assets and liabilities

 

 

 

 

 

 

 

Accounts receivable

 

 

3,366

 

 

2,760

 

Tax credit receivable

 

 

(53,591

)

 

 

Prepaid expenses and other current assets

 

 

44,771

 

 

(33,018

)

Accounts payable and accrued liabilities

 

 

21,526

 

 

(39,530

)

Net cash used in by operating activities

 

 

(11,574

)

 

(36,961

)

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

Purchases of marketable equitable securities

 

 

(28,663

)

 

 

Proceeds from sales of  marketable equitable securities

 

 

63,063

 

 

 

Purchases of fixed assets

 

 

(30,206

)

 

 

 

Net cash provided by investing activities

 

 

4,194

 

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

Proceeds from related party notes payable

 

 

 

 

158,010

 

Payment of related party notes payable

 

 

 

 

(132,810

)

Net cash provided by financing activities

 

 

 

 

25,200

 

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

 

(7,380

)

 

(11,761

)

Cash and cash equivalents, beginning of the period

 

 

19,288

 

 

12,704

 

Cash and cash equivalents, end of the period

 

$

11,908

 

$

943

 

 

 

 

 

 

 

 

 

Supplemental Cash Flow Information

 

 

 

 

 

 

 

Interest Paid

 

$

 

$

5,339

 

Taxes Paid

 

$

 

$

 




The

  Six Months  Six Months 
  Ended  Ended 
  April 30, 2009  April 30, 2009 
  (Unaudited)  (Unaudited) 
Cash Flows from Operating Activities:      
Net loss $(95,168) $(1,225)
Adjustments to reconcile net loss to net cash        
  used in operating activities:        
Accumulated depreciation and amortization  11,149   43,216 
Changes in assets and liabilities        
Accounts receivable  (6,959)  7,492 
Tax credit receivable  (10,561)  (13,714)
Prepaid expenses and other current assets  8,011   9,246 
Accounts payable and accrued liabilities  150,093   27,399 
Deferred revenue  93,500   - 
Net cash provided (used) by operating activities  150,065   72,414 
         
Cash Flows from Investing Activities:        
Purchases of marketable equitable securities  -   (14,408)
Proceeds from sales of  marketable equitable securities  -   34,400 
Prepaid construction costs  -     
Purchases of fixed assets  (150,000)  (29,394)
Net cash used by investing activities  (150,000)  (9,402)
         
Cash Flows from Financing Activities:        
Proceeds from related party notes payable  -   - 
Payment of related party notes payable  -   - 
Net cash provided by financing activities  -   - 
         
Net increase in cash and cash equivalents  65   63,012 
Cash and cash equivalents, beginning of the period  3,135   19,288 
Cash and cash equivalents, end of the period $3,200  $82,300 
See the accompanying notes are an integral part of theseto the financial statements




3

MERA PHARMACEUTICALS INC.

NOTES TO

CONDENSED FINANCIAL STATEMENTS

1.

Basis of Presentation of Financial Statements

1.Basis of Presentation of Financial Statements

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended July 31, 2009April 30, 2010 are not necessarily indicative of the results that may be expected for the year ending October 31, 2009.2010. For further information, refer to the financial statements and footnotes theretoth ereto for the year ended October 31, 2008,2009, included in Form 10-KSB10-K filed wi thwith the Securities and Exchange Commission


The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period.  The more significant areas requiring the use of management’s estimates and assumptions relate to depreciation and amortization calculations; inventory valuations; asset impairments (including impairments of goodwill, long-lived assets, and investments); valuation allowances for deferred tax assets; reserves for contingencies and litigation; and the fair value and   accounting   treatment of financial instruments.  The Company basesbas es its estimates on the Company's historical experience and on various other assumptions that are believed to be reasonable under the circumstances.  According ly,Accordingly, actual results may differ significantly from these estimates under different assumptions or conditions.

2.


2.Going Concern.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  As shown in the accompanying financial statements, the Company has incurred a net loss of $77,778 for the First quarter ending April 30, 2010 and a net accumulated loss of $8,207,026 from October 31, 2002 through April 30, 2010.  The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations from the development and sales from Kona Sea Salt.  Management has plans to seek additional capital through private placement and public offerings of its common stock.  These factors raise substantial doubt that the Company will be able to continue as a going concern.

Management’s plan for the continuation of the Company as a going concern includes financing the Company’s operations through issuance of its common stock.  If the Company is unable to complete its financing requirements or achieve revenue as projected, it will then modify its expenditures and plan of operations to coincide with the actual financing completed and actual operating revenues.  There are no assurances, however, with respect to the future success of these plans.
4

MERA PHARMACEUTICALS
CONDENSED FINANCIAL STATEMENTS

Unless otherwise indicated, amounts provided in these notes to the financial statements pertain to continuing operations.

3. Related Party Transactions.

On November 2, 2009 the Company entered into an agreement with an entity created and controlled by certain members of its Board of Directors.  The agreement involves the purchase by such entity of Bulk Kona Deep Sea Salt from unsold inventory at a price on $7.25 per kilogram.  The Company estimates its direct cost for the material is approximately $5.00 per kilogram.  The purpose of this transaction is, in the absence of any other funding sources to provide the cash flow needed to maintain and grow operations so that the Company is able to produce enough Kona Deep Sea Salt to market and sell outside of Hawaii.  This program will end once the Company is able to attain positive cash flow sufficient to sustain such operations.  Under this agreement, the Company shall have the right of firs t refusal to repurchase some or the entire product purchased by the related entity at a price of $8.50 per kilogram if certain conditions are met.  During the three months ended April 30, 2010 the Company received $58,700 from the related entity under this agreement.  Of this amount $58,700 was recorded as deferred revenue resulting for product that had not yet been shipped.
4.   Summary of Significant Accounting Policies


Revenue Recognition.  The Company has adopted Securities and Exchange Commission’s (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements.  Product revenue is recognized upon shipment to customers. Contract services revenue is recognized as services are performed on a cost reimbursement basis. Royalties are recognized upon receipt.

3.

5.  Recent Accounting Pronouncements

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.

5

MERA PHARMACEUTICALS
CONDENSED FINANCIAL STATEMENTS

Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles


In June 2009, the Financial Accounting Standards Board “FASB” issued Statement of Financial Accounting Standard (“SFAS”) No. 168, “The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles” (“SFAS No. 168”).  SFAS No. 168 will become the single source of authoritative nongovernmental U.S. generally accepted accounting principles (“GAAP”), superseding existing FASB, American Institute of Certified Public Accountants (“AICPA”), Emerging Issues Task Force (“EITF”), and related accounting literature.  SFAS No. 168 reorganizes the thousands of GAAP pronouncements into roughly 90 accounting topics and displays them using a consistent structure.  Also included is relevant SecuritiesSecuritie s and Exchange Commission guidance organized using the same topical structure in separate sections.  SFAS No. 168 wi llwill be effective for financial statements issued for reporting periods that end after September 15, 2009.  This statement will have an impact on the Company’s financial statements since all future references to authoritative accounting literature will be references in accordance with SFAS No. 168.



6



MERA PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS


Subsequent Events

In May 2009, the FASB issued SFAS No. 165, “Subsequent Events”.(“SFAS No. 165”) This Statement establishes general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued.  It requires the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date and is effective for interim and annual periods ending after June 15, 2009.  The adoption of SFAS No. 165 did not have a material impact on the Company’s financial statements.


Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly


In April 2009, the FASB issued FSP FAS No. 157-4, “Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly". This FSP provides additional guidance for estimating fair value in accordance with FASB Statement No. 157, Fair Value Measurements, when the volume and level of activity for the asset or liability have significantly decreased. This FSP also includes guidance on identifying circumstances that indicate a transaction is not orderly. FSP FAS No. 157-4 is effective for interim and annual reporting periods ending after June 15, 2009, and shall be applied prospectively. The implementation of FSP FAS No. 157-4 did not have a material on the Company’s financial position and results of operations.


Recognition and Presentation of Other-Than-Temporary Impairments


In April 2009, the FASB issued FSP FAS No. 115-2 and FAS No. 124-2, “Recognition and Presentation of Other-Than-Temporary Impairments ". The objective of an other-than-temporary impairment analysis under existing U.S. generally accepted accounting principles (GAAP) is to determine whether the holder of an investment in a debt or equity security for which changes in fair value are not regularly recognized in earnings (such as securities classified as held-to-maturity or available-for-sale) should recognize a loss in earnings when the investment is impaired. An investment is impaired if the fair value of the investment is less than its amortized cost basis. FSP FAS No. 115-2 and FAS No. 124-2 is effective for interim and annual reporting periods ending after June 15, 2009, with early adoption permitted for periods ending after MarchMar ch 15, 2009. Earlier adoption for periods ending before M archMarch 15, 2009, is not permitted.  The implementation of FSP FAS No. 115-2 and FAS No. 124-2 did not have a material impact on the Company’s financial position and results of operations.


6

MERA PHARMACEUTICALS
CONDENSED FINANCIAL STATEMENTS
Interim Disclosures about Fair Value of Financial Instruments

In April 2009, the FASB issued FSP FAS No. 107-1 and APB No. 28-1, “Interim Disclosures about Fair Value of Financial Instruments". This FSP amends SFAS No. 107,Disclosures about Fair Value of Financial Instruments,to require disclosures about fair value of financialinstrumentsfinancial instruments for interim reporting periods of publicly traded companies as well as in annualfinancialannual financial statements. This FSP also amends APB Opinion No. 28,Interim Financial Reporting,to require those disclosures in summarized financial information at interim reporting periods. FSP FAS No. 107-1 is effective for interim reporting periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009.  The implementation of FSP FAS No. 107-1 did not have a material impact on the Company’s financial position and results of operations


Amendments to the Impairment Guidance of EITF Issue No. 99-20


In January 2009, the FASB issued FSP Emerging Issues Task Force ("EITF") Issue No. 99-20-1, “Amendments to the Impairment Guidance of EITF Issue No. 99-20". This FSP amends the impairment guidance in EITF Issue No. 99-20, “Recognition of Interest Income and Impairment on Purchased Beneficial Interests and Beneficial Interests That Continue to Be Held by a Transferor in Securitized Financial Assets,” to achieve more consistent determination of whether an other-than-temporary impairment has occurred. The FSP also retains and emphasizes the objective of an other than- temporary impairment assessment and the related disclosure requirements in FASB Statement No. 115,Accounting for Certain Investments in Debt and Equity Securities,and other related guidance. This IssueI ssue is effective for interim and annual reporting periods ending after December 15, 2008, and shall



7



MERA PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS


be applied prospectively. Retrospective application to a prior interim or annual reporting period is not permitted. The adoption of FSP EITF 99-20-1 did not have a material effect on the Company’s financial statements

Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance or Other Financing


In June 2009, the FASB issued FSP Emerging Issues Task Force ("EITF") Issue No. 09-1, “Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance or Other Financing”. This Issue is effective for fiscal years beginning on or after December 15, 2009, and interim periods within those fiscal years for arrangements outstanding as of the beginning of those fiscal years. Share lending arrangements that have been terminated as a result of counterparty default prior to the effective date of this Issue but for which the entity has not reached a final settlement as of the effective date are within the scope of this Issue. This Issue requires retrospective application for all arrangements outstanding as of the beginning of fiscal years beginningbe ginning on or after December 15, 2009. This Issue is effective for arrangements entered into on or after the beginning of the first r eportingreporting period that begins on or after June 15, 2009. Early adoption is not permitted. The Company is currently assessing the impact of FSP EITF 09-1 on its financial position and results of operations.

4.

Material Agreements

The Company has received licensing income under a license agreement with HR BioPetroleum, Inc (HRBP) that was signed in fiscal 2007. The agreement calls for the Company to receive $22,000 per month and grants HRBP access and use of the Companies facilities to perform a research project relating to large-scale cultivation and production of certain microalgae species, and grants HRBP license rights to a patent and other intellectual property owned by the Company. On January 9, 2009, the Company was informed that HRBP would not be renewing such license agreement. Revenues received under this agreement ceased effective July 8, 2009.




7



ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


This Report contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements that include the words "believes," "expects," "estimates," "anticipates" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.  Risk factors include, but are not limited to, our ability to raise or generate additional capital; our ability to cost-effectively manufacture our products on a commercial scale; the concentration of our current customer base; competition; our ability to comply with applicable regulatory requirements; potential need for expansion of our production facility; the potential loss of a strategic relationship; inability to attract and retain key personnel; management's ability to effectively manage our growth; difficulties and resource constraints in developing new products; protection and enforcement of our intellectual property; compliance with environmental laws; climate uncertainty; currency fluctuations; exposure to product liability lawsuits; and control of our management and affairs by principal stockholders.


The reader should carefully consider, together with the other matters referred to herein, the information contained under the caption "Risk Factors" in our Annual Report on Form 10-KSB10-K for a more detailed description of these significant risks and uncertainties.  We caution the reader, however, that these factors may not be exhaustive.


Since inception, our primary operating activities have consisted of basic research and development and production process development, recruiting personnel, purchasing operating assets, raising capital and sales of product.  From September 16, 2002, the effective date of our plan of reorganization, through July 31, 2009April 30, 2010 we had an accumulated deficit of $8,011,449.$8,207,026. Our losses to date have resulted primarily from costs incurred in research and development, production costs and from general and administrative expenses associated with operations.  We expect to continue to incur smaller operating losses through the current fiscal year.  We also expect to have quarter-to-quarter and year-to-year fluctuations in revenues, expenses and losses, some of which could be significant.

8


We have a limited operating history.  An assessment of our prospects should include the technology risks, market risks, expenses and other difficulties frequently encountered by early-stage operating companies, and particularly companies attempting to enter competitive industries with significant technology risks and barriers to entry.  We have attempted to address these risks by, among other things, hiring and retaining highly qualified persons, diversifying our customer base and expanding revenue sources, e.g., by performing other contract services and increasing efforts to sell raw materials to other product formulators.  However, our best efforts cannot guarantee that we will overcome these risks in a timely manner, if at all.


Results of Operations


Revenues.Revenue declined 38.6%70.3% for the quarter ending July 31, 2009April 30, 2010 to $106,213$61,413 vs. $173,098$206,762 in the year ago quarter ending July 31, 2008.April 30, 2009.  The revenue decline was mostlypartially attributable to the ending of the HRBioPetroleum agreement which ended on June 8, 2009

2009.  Product sales of AstaFactor and Kona Sea Salt decreased to $61,413 versus $96,215 in the comparable periods, an decrease of 36.2%

Cost of Sales.Cost of goods sold was $12,851$9,095 for the quarter ending July 31, 2009April 30, 2010 versus $3,489$1,306 in the quarter ending July 31, 2008April 30, 2009 which was a 268%696% increase as we added materials and inventory to meet expected future sales of our AstaFactor and Kona Sea Salt products.


Research and Development Costs.Research and development costs increaseddecreased to $82,658$70,474 for the quarter ending July 31, 2009April 30, 2010 versus $64,714$72,788 for the quarter ending July 31, 2008,April 30, 2009, an increasedecrease of approximately 27.7%3.2%.  The increasedecrease was due to the winding down of costs associated with the conclusion of the Company’s technical service agreement and shift of personnel to work on research for the introduction of future new products that the Company hopes to introduce in the future.

products.


Selling, General and Administrative Expenses.   These expenses increaseddecreased to $88,073$56,491 for the quarter ending July 31, 2009April 30, 2010 as compared with $38,970$93,394 in the quarter ending July 31, 2008,April 30, 2009, a increasedecrease of  126%39.5% as the Company, due to increased salesconcluded the technical service agreement and revenue, hired additional sales and support staff to enable the Company to grow its sales and marketing division.employees associated with that project.  The Company will also continue to contain expenses though the use of part time workers who are available on a call basis when needed.





Interest Expense.  For the quarter ended July 31,April 30, 2010 versus 2009, versus 2008, interest expense was $1,248 and $3,310,$1,248, respectively. This decrease was due to a lower level of borrowing by the Company during the third quarter of 2009 compared to the third quarter of 2008.

9


ITEM 3.

CONTROLS AND PROCEDURES


(a)  Evaluation of Disclosure Controls and Procedures.  Under the supervision and with the participation of our management, including our chief executive officer, we conducted an evaluation of our disclosure controls and procedures, as such terms are defined in Rule 13a-14(c) promulgated under the Exchange Act, within the 90 day period prior to the filing date of this quarterly report.  Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer concluded that our disclosure controls and procedures were effective as of that date.


(b) There have been no significant changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation referenced in paragraph (a) above.



10



PART II - OTHER INFORMATION


ITEM 1.

LEGAL PROCEEDINGS


None.


ITEM 2.

CHANGES IN SECURITIES


None.


ITEM 3.

DEFAULTS UPON SENIOR SECURITIES


None.


ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

  (REMOVED AND RESERVED)

ITEM 5.

OTHER INFORMATION


None.



11

ITEM 6.

EXHIBITS AND REPORTS ON FORM 8-K

None.

a.

EXHIBITS

31.1

Certification of Chief Executive Officer pursuant to Rule 13a – 14 (a) of the Securities Exchange Act of 1934 (filed herewith electronically).

31.2

Certification of Principal Financial and Accounting Officer pursuant to Rule 13a – 14 (a) of the Securities Exchange Act of 1934 (filed herewith electronically).

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith electronically).

32.2

Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes – Oxley Act of 2002 (filed herewith electronically)

b.

REPORTS ON FORM 8-K

None.




Certification of Chief Executive Officer pursuant to Rule 13a – 14 (a) of the Securities Exchange Act of 1934 (filed herewith electronically).

Certification of Principal Financial and Accounting Officer pursuant to Rule 13a – 14 (a) of the Securities Exchange Act of 1934 (filed herewith electronically).

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith electronically).

Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes – Oxley Act of 2002 (filed herewith electronically)



12

SIGNATURES


Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

MERA PHARMACEUTICALS, INC.

Dated:  June 14, 2010

By:

Dated: Sept 09, 2009                                                       

By:

/s/ GREGORY F. KOWAL

 /s/ Gregory F. Kowal

Gregory F. Kowal

Chief Executive Officer




12


13